Examples include (i) “low” PSMA uptake in a slightly enlarged lymph node (s) in men with newly diagnosed or recurrent ...

Contemporary PET imaging has transitioned from a metabolic approach largely dominated by [¹⁸F]FDG to a multifaceted molecular platform encompassing a ...

The prospective, multi-center phase 3 PRIMARY randomized trial tested the additive diagnostic value of PSMA PET imaging in high-risk men with negative or equivocal MRI in the diagnosis of significant ...

The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. William Maguire discussing regulatory considerations related to PSMA PET imaging in clinical trials.

LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Dr George Owiti, a radiographer at Kericho County Hospital examines the Chest CT results of a patient admitted to the hospital. [James Wanzala, Standard] Despite recent breakthroughs that have ...